Clarivate (NYSE:CLVT) Stock Price Up 7% – Time to Buy?

Shares of Clarivate PLC (NYSE:CLVT) rose 7% during mid-day trading on Thursday . The company traded as high as $2.41 and last traded at $2.3750. Approximately 1,363,752 shares were traded during trading, a decline of 80% from the average daily volume of 6,657,492 shares. The stock had previously closed at $2.22.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CLVT. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research report on Wednesday, June 24th. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Citigroup decreased their price target on Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $3.22.

Clarivate Stock Up 11.5%

The stock has a market capitalization of $1.58 billion, a PE ratio of -11.79 and a beta of 1.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84. The business’s fifty day moving average price is $2.42 and its two-hundred day moving average price is $2.59.

Clarivate (NYSE:CLVT) last issued its earnings results on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The company had revenue of $585.50 million during the quarter, compared to analyst estimates of $569.50 million. During the same quarter last year, the business posted $0.14 EPS. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, equities research analysts forecast that Clarivate PLC will post 0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Clarivate

A number of institutional investors and hedge funds have recently modified their holdings of CLVT. American Century Companies Inc. boosted its position in Clarivate by 20.6% in the third quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock valued at $38,200,000 after buying an additional 1,706,306 shares during the last quarter. Iridian Asset Management LLC CT raised its position in Clarivate by 52.4% during the 4th quarter. Iridian Asset Management LLC CT now owns 1,528,410 shares of the company’s stock worth $5,105,000 after buying an additional 525,452 shares during the last quarter. Cove Street Capital LLC lifted its stake in Clarivate by 4,075.2% during the 3rd quarter. Cove Street Capital LLC now owns 452,462 shares of the company’s stock valued at $1,733,000 after acquiring an additional 441,625 shares during the period. BW Gestao de Investimentos Ltda. lifted its stake in Clarivate by 51.7% during the 4th quarter. BW Gestao de Investimentos Ltda. now owns 4,345,321 shares of the company’s stock valued at $14,513,000 after acquiring an additional 1,480,300 shares during the period. Finally, LSV Asset Management lifted its stake in Clarivate by 25.6% during the 4th quarter. LSV Asset Management now owns 2,647,900 shares of the company’s stock valued at $8,844,000 after acquiring an additional 540,400 shares during the period. Institutional investors and hedge funds own 85.72% of the company’s stock.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.